Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
183 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2016', provides an overview of the Cytomegalovirus (HHV-5) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections - The report reviews pipeline therapeutics for Cytomegalovirus (HHV-5) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Cytomegalovirus (HHV-5) Infections therapeutics and enlists all their major and minor projects - The report assesses Cytomegalovirus (HHV-5) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Cytomegalovirus (HHV-5) Infections Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Cytomegalovirus (HHV-5) Infections Overview 10 Therapeutics Development 11 Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview 11 Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis 12 Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies 13 Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes 15 Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Cytomegalovirus (HHV-5) Infections - Products under Development by Companies 20 Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes 23 Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development 24 Adicet Bio, Inc. 24 AIMM Therapeutics B.V. 25 Altor BioScience Corporation 26 Astellas Pharma Inc. 27 Atara Biotherapeutics, Inc. 28 Bionor Pharma ASA 29 Biotest AG 30 Cell Medica Limited 31 Chimerix, Inc. 32 China Biologic Products, Inc. 33 CyTuVax B.V. 34 Fate Therapeutics, Inc. 35 GlaxoSmithKline Plc 36 Hookipa Biotech AG 37 Humabs BioMed SA 38 Kadmon Corporation, LLC 39 Laboratoires Thea S.A. 40 Merck & Co., Inc. 41 Microbiotix, Inc. 42 Novartis AG 43 Pfizer Inc. 44 Phoenix Biotechnology, Inc. 45 Savoy Pharmaceuticals, Inc. 46 Sigma-Tau S.p.A. 47 Trellis Bioscience, Inc. 48 Vakzine Projekt Management GmbH 49 VBI Vaccines Inc. 50 Vical Incorporated 51 Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Combination Products 53 Assessment by Target 54 Assessment by Mechanism of Action 56 Assessment by Route of Administration 58 Assessment by Molecule Type 60 Drug Profiles 62 AIC-387 - Drug Profile 62 AIC-476 - Drug Profile 63 AIC-813 - Drug Profile 64 AL-18 - Drug Profile 65 Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections - Drug Profile 66 Antibody for Human Cytomegalovirus Infection - Drug Profile 67 Antiviral TCR-Ck - Drug Profile 68 Antiviral TCR-Ig - Drug Profile 69 ASP-0113 - Drug Profile 70 brincidofovir - Drug Profile 71 BT-084 - Drug Profile 74 Cell Therapy 3 For CMV - Drug Profile 75 Cell Therapy for Cytomegalovirus Infections - Drug Profile 76 Cellular Immunotherapy for CMV Infections - Drug Profile 77 Cellular Immunotherapy for Cytomegalovirus and Adenovirus Infections - Drug Profile 78 Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 79 Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 80 Cellular Immunotherapy for Cytomegalovirus Infections - Drug Profile 81 Cellular Immunotherapy for Cytomegalovirus Infections and GBM - Drug Profile 82 Cellular Immunotherapy for Infectious Disease - Drug Profile 83 Cellular Immunotherapy for Infectious Diseases - Drug Profile 84 Cellular Immunotherapy for Viral Infections - Drug Profile 85 Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile 86 Cellular Immunotherapy to Target CMV Antigen for Cytomegalovirus Infections - Drug Profile 87 Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 88 Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 90 CMX-669 - Drug Profile 91 CSJ-148 - Drug Profile 92 CyMVectin - Drug Profile 93 cytomegalovirus (virus like particle) vaccine - Drug Profile 94 Cytomegalovirus vaccine - Drug Profile 95 Cytomegalovirus vaccine - Drug Profile 96 Cytomegalovirus vaccine - Drug Profile 98 Cytomegalovirus vaccine 1 - Drug Profile 99 Cytomegalovirus vaccine 2 - Drug Profile 101 Cytovir-CMV - Drug Profile 102 filociclovir - Drug Profile 104 ganciclovir - Drug Profile 106 Gene Therapy for Cytomegalovirus Infections - Drug Profile 107 HB-101 - Drug Profile 108 letermovir - Drug Profile 109 maribavir - Drug Profile 110 MBX-2168 - Drug Profile 112 Monoclonal Antibody for Cytomegalovirus Infections - Drug Profile 113 Monoclonal Antibody for HCMV Infections - Drug Profile 114 Monoclonal Antibody to Agonize LTbR for CMV Infection - Drug Profile 115 Peptides to Inhibit Heparan Sulfate for HHV-5 Infections - Drug Profile 117 ProTmune - Drug Profile 118 PTX-3 - Drug Profile 119 RBT-301 - Drug Profile 120 Recombinant Peptide for Infectious Diseases - Drug Profile 121 RKP-00156 - Drug Profile 122 Small Molecule for Cytomegalovirus - Drug Profile 123 Small Molecules for CMV Infections - Drug Profile 124 Small Molecules for CMV infections and Cancer - Drug Profile 125 Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 126 Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile 127 Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases - Drug Profile 128 Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections - Drug Profile 129 TRL-345 - Drug Profile 130 V-160 - Drug Profile 131 Vacc-CMV - Drug Profile 132 Vaccine for Cytomegalovirus Infection and Glioblastoma Multiforme - Drug Profile 133 VBI-1501A - Drug Profile 134 Viralym-C - Drug Profile 135 Viroprev - Drug Profile 136 VPM-2001 - Drug Profile 137 Cytomegalovirus (HHV-5) Infections - Recent Pipeline Updates 138 Cytomegalovirus (HHV-5) Infections - Dormant Projects 161 Cytomegalovirus (HHV-5) Infections - Discontinued Products 166 Cytomegalovirus (HHV-5) Infections - Product Development Milestones 167 Featured News & Press Releases 167 Appendix 178 Methodology 178 Coverage 178 Secondary Research 178 Primary Research 178 Expert Panel Validation 178 Contact Us 178 Disclaimer 179
List of Tables
Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2016 15 Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H1 2016 16 Number of Products under Development by Companies, H1 2016 17 Number of Products under Development by Companies, H1 2016 (Contd..1) 18 Number of Products under Investigation by Universities/Institutes, H1 2016 19 Comparative Analysis by Late Stage Development, H1 2016 20 Comparative Analysis by Clinical Stage Development, H1 2016 21 Comparative Analysis by Early Stage Development, H1 2016 22 Comparative Analysis by Unknown Stage Development, H1 2016 23 Products under Development by Companies, H1 2016 24 Products under Development by Companies, H1 2016 (Contd..1) 25 Products under Development by Companies, H1 2016 (Contd..2) 26 Products under Investigation by Universities/Institutes, H1 2016 27 Cytomegalovirus (HHV-5) Infections - Pipeline by Adicet Bio, Inc., H1 2016 28 Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics B.V., H1 2016 29 Cytomegalovirus (HHV-5) Infections - Pipeline by Altor BioScience Corporation, H1 2016 30 Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc., H1 2016 31 Cytomegalovirus (HHV-5) Infections - Pipeline by Atara Biotherapeutics, Inc., H1 2016 32 Cytomegalovirus (HHV-5) Infections - Pipeline by Bionor Pharma ASA, H1 2016 33 Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, H1 2016 34 Cytomegalovirus (HHV-5) Infections - Pipeline by Cell Medica Limited, H1 2016 35 Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix, Inc., H1 2016 36 Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products, Inc., H1 2016 37 Cytomegalovirus (HHV-5) Infections - Pipeline by CyTuVax B.V., H1 2016 38 Cytomegalovirus (HHV-5) Infections - Pipeline by Fate Therapeutics, Inc., H1 2016 39 Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, H1 2016 40 Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Biotech AG, H1 2016 41 Cytomegalovirus (HHV-5) Infections - Pipeline by Humabs BioMed SA, H1 2016 42 Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corporation, LLC, H1 2016 43 Cytomegalovirus (HHV-5) Infections - Pipeline by Laboratoires Thea S.A., H1 2016 44 Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co., Inc., H1 2016 45 Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix, Inc., H1 2016 46 Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H1 2016 47 Cytomegalovirus (HHV-5) Infections - Pipeline by Pfizer Inc., H1 2016 48 Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology, Inc., H1 2016 49 Cytomegalovirus (HHV-5) Infections - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 50 Cytomegalovirus (HHV-5) Infections - Pipeline by Sigma-Tau S.p.A., H1 2016 51 Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience, Inc., H1 2016 52 Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H1 2016 53 Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc., H1 2016 54 Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Incorporated, H1 2016 55 Assessment by Monotherapy Products, H1 2016 56 Assessment by Combination Products, H1 2016 57 Number of Products by Stage and Target, H1 2016 59 Number of Products by Stage and Mechanism of Action, H1 2016 61 Number of Products by Stage and Route of Administration, H1 2016 63 Number of Products by Stage and Molecule Type, H1 2016 65 Cytomegalovirus (HHV-5) Infections Therapeutics - Recent Pipeline Updates, H1 2016 142 Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2016 165 Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..1), H1 2016 166 Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..2), H1 2016 167 Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..3), H1 2016 168 Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..4), H1 2016 169 Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2016 170
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
